ClinicalTrials.gg
CompletedNCT00064415Updated Feb 22, 2012

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

A Phase 3 interventional study of arformoterol and Salmeterol in Chronic Obstructive Pulmonary Disease, Chronic Bronchitis and Emphysema, sponsored by Sumitomo Pharma America, Inc.. Completed at 90 sites in United States. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2012-02-22.

Primary conditionBronchitis, ChronicRegistry: Pulmonary Disease, Chronic ObstructiveReclassifiedWhy we changed it
Registry
Pulmonary Disease, Chronic Obstructive — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bronchitis, Chronic
Why
  1. The study's listed conditions name Bronchitis, Chronic, a narrower term within Pulmonary Disease, Chronic Obstructive.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
799
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 100 studies in Bronchitis, Chronic with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Bronchitis, Chronic · United States.

Enrollment
9th of 82
799 · median 126
Started
2002
with 4 others
Phase 3
19 of 100
none open now
Registered
3rd of 100
by date
Lead sponsor
7 of 100
Sumitomo Pharma America, Inc.

Among the 100 studies in Bronchitis, Chronic with a site in United States, this one is the 9th largest by enrollment of the 82 interventional ones that give a count, is one of 5 that started in 2002, is one of 19 in phase 3, and was the 3rd registered.

Bronchitis, Chronic

209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.

Browse Bronchitis, Chronic studies →

Open to participants now

7 of the 100 studies in Bronchitis, Chronic with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Bronchitis, Chronic studies recruiting now, 5 (50%) set no upper age limit and 2 (20%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Bronchitis, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD

Read the detailed description

This was a multicenter, open-label, randomized, active controlled, parallel group chronic safety study of arformoterol 50 mcg once daily over a period of 12 months in subjects with COPD. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Chronic Bronchitis
  • Emphysema

Browse trials for

04

In context

Bronchitis, Chronic Reclassified

209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.

This study's enrollment of 799 is above the median of 101 across 154 interventional studies indexed under Bronchitis, Chronic.

Browse Bronchitis, Chronic studies →

Lead sponsor

Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.

First submitted before Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd..

Compared within Bronchitis, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pulmonary Disease, Chronic Obstructive. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

INCLUSION CRITERIA: In order to qualify for participation, subjects must meet the following criteria:

  • Must give written prior to participation. Women of must also sign the Women of Childbearing Potential Addendum.
  • Must be willing to comply with study procedures and visit schedule
  • Male or female >35 years of age
  • Female subjects \<65 years of age must have a serum pregnancy test conducted at Visit 1 and confirmed negative prior to randomization. Subjects of childbearing potential must be using an acceptable method of .
  • Female subjects who are considered not of childbearing potential must be: (1) documented surgically sterile, OR (2)
  • Have a primary diagnosis of , which may include components of chronic bronchitis and/or emphysema. Diagnosis can be made during the screening process.
  • Have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years)
  • Medical Research Council (MRC) Dyspnea Scale Score >2
  • Have a baseline \<65% of predicted normal value and >0.70 L documented prior to randomization
  • Have an FEV1/FVC ratio \<70% documented prior to randomization.
  • Have a chest x-ray that is consistent with the diagnosis of COPD and taken \<3 months prior to Visit 1. If there is no chest x-ray taken 3 months prior to Visit 1, a chest x-ray will be performed prior to Visit 2.
  • Be able to complete all study questionnaires and logs reliably

EXCLUSION CRITERIA: In order to qualify for participation, subjects must not meet any of the following criteria:

  • Currently using disallowed medications or will be unable to complete the medication
  • Female subject who is pregnant or lactating
  • Have participated in an drug study within 30 days prior to Visit 1 or who is currently participating in another investigational drug study
  • Subject whose schedule or travel prevents the completion of all required visits
  • Subject who is scheduled for in-patient hospitalization, including elective surgery (in-patient or out-patient) during the trial.
  • Subject with life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days prior to Visit 1
  • Known history of asthma or any chronic respiratory disease (including a current history of sleep apnea) other than COPD (chronic bronchitis and/or emphysema).
  • Subject with a blood eosinophil count >5%
  • Subject with cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol
  • History of cancer except non-melanomatous skin cancer
  • History of lung resection of more than one full lobe
  • Subject who requires continuous supplemental oxygen therapy. The use of supplemental oxygen, not to exceed 2 L/minute, at nighttime only and/or only during exercise is allowed.
  • Have had a change in dose or type of any medications for COPD within 14 days prior to the screening visit
  • Have a known sensitivity to (R,R)-formoterol, ipratropium, salmeterol or albuterol or any of the contained in any of these formulations
  • Have clinically significant abnormalities that may interfere with the metabolism or excretion of the study drug
  • Have a history of substance abuse or drug abuse within 12 months of Visit 1 or with a positive urine drug screen at the screening visit
  • Subject with clinically significant abnormal laboratory values
  • Subject with clinically significant abnormal 12-lead that may jeopardize the subject's ability to complete the study
  • Subject using any prescription drug for which concomitant beta-agonist administration is
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
799 participants (actual)

Study arms

  • Experimental
    1

    Arformoterol tartrate 50 mcg QD

    Drug: arformoterol

  • Active comparator
    2

    Salmeterol 42 mcg BID

    Drug: Salmeterol

Interventions

  • Arformoterol inhalation solution, 50 mcg QD

    Also known as: Brovana Inhalation Solution, (R,R)-Formoterol

  • Salmeterol MDI, 42 mcg BID

    Also known as: Serevent MDI, racemic formoterol

07

What researchers measure

Primary outcomes

  1. Overall occurrence of adverse events

    Time frame: Weeks -1, 0, 3, 6, 9, 13, 26, 39, 52

Secondary outcomes

  1. Laboratory parameters

    Time frame: Weeks -1, 0, 3, 6, 9, 13, 26, 39, 52

  2. ECG parameters

    Time frame: Weeks -1, 0, 3, 6, 9, 13, 26, 39, 52

  3. 24-hour holter monitoring parameters

    Time frame: Weeks -1, 0, 13, 26, 39, 52

  4. Vital signs

    Time frame: Weeks -1, 0, 3, 6, 9, 13, 26, 39, 52

  5. Plasma arformoterol concentrations

    Time frame: Weeks -1, 0, 3, 6, 9, 13, 26, 39, 52

  6. Physical examination findings

    Time frame: Weeks -1, 53

08

Study locations

90 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • Princeton Pulmonary Group, PC
    Birmingham, Alabama 35211, United States
  • Pulmonary & Sleep Associates of Jasper, PC
    Jasper, Alabama 35501, United States
  • Pulmonary Associates of Mobile, P.C.
    Mobile, Alabama 36608, United States
  • Arizona Clinical Research Center, Inc.
    Tucson, Arizona 85712, United States
  • Northern California Research Corp.
    Fair Oaks, California 95628, United States
  • SARC Research Center
    Fresno, California 93720, United States
  • Irvine Center for Clinical Research
    Irvine, California 92618, United States
  • Scripps Clinic - Chest and Critical Care
    LaJolla, California 92037, United States
  • Torrance Clinical Research
    Los Angeles, California 90505, United States
  • Facey Medical Center - Radiant Research
    Mission Hills, California 91345, United States
  • Office of Delmer Henninger, MD
    Murrieta, California 92562, United States
  • Advanced Clinical Research Institute
    Orange, California, United States
  • Center for Clinical Trials, LLC
    Paramount, California 90723, United States
  • Advances in Medicine
    Rancho Mirage, California 92270, United States
  • Inland Clinical Research, Inc.
    Riverside, California 92501, United States
  • Institute of Healthcare Assessment, Inc.
    San Diego, California 92120, United States
  • Wetlin Research Associates, Inc.
    San Diego, California 92120, United States
  • San Jose Clinical Research, Inc.
    San Jose, California 95128, United States
  • West Coast Clinical Trials
    Signal Hill, California 90755, United States
  • Allergy & Asthma Medical Group of Diablo Valley, Inc.
    Walnut Creek, California 94598, United States
  • Northern Colorado Pulmonary Consultants, PC
    Ft. Collins, Colorado 80528, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • University Clinical Research, DeLand
    DeLand, Florida 32720, United States
  • nTouch Research
    Melbourne, Florida 32901, United States
  • nTouch Research
    St. Petersburg, Florida 33710, United States
  • USF Asthma, Allergy and Immunology
    Tampa, Florida 33613, United States
  • AHS Medical Research, Inc.
    Tampa, Florida 33615, United States
  • New Horizon Health Research
    Atlanta, Georgia, United States
  • Protocare Trial, Inc.
    Austell, Georgia 30106, United States
  • nTouch Research
    Decatur, Georgia 30033, United States
  • Marietta Pulmonary Medicine
    Marietta, Georgia 30060, United States
  • North Point Pulmonary Associates
    Roswell, Georgia 30076, United States
  • Pulmonary Consultants
    Coeur d'Alene, Idaho 83814, United States
  • University of Chicago - Department of Medicine
    Chicago, Illinois 60637, United States
  • Sneeze, Wheeze and Itch, LLC
    Normal, Illinois 61761, United States
  • Medisphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • South Bend Clinic
    South Bend, Indiana 46617, United States
  • Heart of America Research Institute
    Shawnee Mission, Kansas 66216, United States
  • Bendel Medical Associates
    Lafayette, Louisiana 70503, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • North Shore Research Associates
    Slidell, Louisiana 70461, United States
  • Office of Paul A. Shapero, MD, PA
    Bangor, Maine 04401, United States
  • Primary Care Cardiology Research, Inc.
    Ayer, Massachusetts 01432, United States
  • Center for Clinical Research
    Taunton, Massachusetts 02780, United States
  • ClinSite, Inc.
    Ann Arbor, Michigan 48106, United States
  • Minnesota Lung Center
    Minneapolis, Minnesota 55407, United States
  • MedEx HealthCare Research, Inc.
    Saint Louis, Missouri 63108, United States
  • Midwest Chest Consultants, PC
    St. Charles, Missouri 63301-2847, United States
  • C.A.R.E Clinical Research
    St. Louis,, Missouri 63122, United States
  • Office of Keith Popovich, MD
    Butte, Montana 59701, United States
  • Montana Medical Research, LLC
    Missoula, Montana 59804, United States
  • Clinical Research Center of Nevada
    Las Vegas, Nevada 89104, United States
  • Advanced Biomedical Research of America
    Las Vegas, Nevada 89119, United States
  • Atlantic Research Associates, Inc.
    Margate City, New Jersey 08402, United States
  • UrgentMed Family Practice Medical
    South Bound Brook, New Jersey 08880, United States
  • Lovelace Scientific Resources - NM
    Albuquerque, New Mexico 87108, United States
  • Endwell Family Physicians
    Endwell, New York 13760, United States
  • Asthma & Allergy Associates, PC
    Ithaca, New York 14850, United States
  • N.Y. Pulmonary Associates
    New York City, New York 10016, United States
  • Ridgewood Medical Group
    Rochester, New York 14626, United States
  • Charlotte Lung and Health Center
    Charlotte, North Carolina 28207, United States
  • North Carolina Clinical Research
    Raleigh, North Carolina, United States
  • New Hanover Medical Research
    Wilmington, North Carolina 28412, United States
  • Odyssey Research Services
    Fargo, North Dakota 58104, United States
  • Community Research Management Associates, Inc.
    Cincinnati, Ohio 45219, United States
  • New Horizons Clinical Research, Inc.
    Cincinnati, Ohio 45241, United States
  • COR Clinical Research LLC
    Oklahoma City, Oklahoma 73103, United States
  • Healthcare Research Consultants
    Tulsa, Oklahoma 74135, United States
  • Clinical Research Institute of Southern Oregon, PC
    Medford, Oregon 97504, United States
  • Medford Medical Clinic, LLP
    Medford, Oregon 97504, United States
  • Allergy Associates Research Center
    Portland, Oregon 97213, United States
  • Northeast Clinical Research Center, Inc.
    Allentown, Pennsylvania 18104, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Consortium Clinical Research, Ltd.
    Ridley Park, Pennsylvania 19078, United States
  • Safe Harbor Clinical Research
    East Providence, Rhode Island 02914, United States
  • Spartanburg Pharmaceutical Research
    Spartanburg, South Carolina 29307, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Ben Taub General Hospital
    Houston, Texas 77030, United States
  • S.W. Asthma Institute
    Houston, Texas 77074, United States
  • Breath of Life Research Institute
    Houston, Texas 77084, United States
  • Wellmed at Northern Hills
    San Antonio, Texas 78217, United States
  • Medsource, Inc.
    Chesapeake, Virginia 23321, United States
  • Pulmonary Associates of Fredericksburg, Inc.
    Fredericksburg, Virginia 22401, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23225, United States
  • Commonwealth Clinical Research
    Richmond, Virginia 23226, United States
  • Virginia Adult & Pediatric Allergy & Asthma, PC Research Office
    Richmond, Virginia 23229, United States
  • Pulmonary Research Partners, Inc.
    South Boston, Virginia 24592, United States
  • Pulmonary Consultants, PLLC
    Tacoma, Washington 98405, United States
  • Morgantown Pulmonary Associates
    Morgantown, West Virginia 26505, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Dec 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2003
First posted
Jul 9, 2003
Start
Jun 2002
Primary completionActual
Dec 2004
CompletionActual
Dec 2004
Last update
Feb 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00064415
Responsible party
Sponsor
First posted
Jul 9, 2003
Start date
Jun 2002
Primary completion
Dec 2004
Completion
Dec 2004
Last update
Feb 22, 2012

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion